Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 8.1% – Time to Buy?

Shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) traded up 8.1% during mid-day trading on Monday . The stock traded as high as $1.38 and last traded at $1.33. 384,307 shares traded hands during mid-day trading, an increase of 137% from the average daily volume of 162,267 shares. The stock had previously closed at $1.23.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wall Street Zen downgraded Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Tiziana Life Sciences Stock Up 8.1%

The stock’s 50 day simple moving average is $1.31 and its two-hundred day simple moving average is $1.36.

Tiziana Life Sciences (NASDAQ:TLSA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Tiziana Life Sciences

A number of large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new position in Tiziana Life Sciences during the first quarter valued at approximately $25,000. Rachor Investment Advisory Services LLC bought a new stake in shares of Tiziana Life Sciences during the 4th quarter worth approximately $25,000. Bison Wealth LLC bought a new stake in shares of Tiziana Life Sciences during the 4th quarter worth approximately $30,000. HRT Financial LP acquired a new stake in shares of Tiziana Life Sciences in the 4th quarter valued at approximately $36,000. Finally, Marshall Wace LLP acquired a new stake in shares of Tiziana Life Sciences in the 2nd quarter valued at approximately $39,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.